Shingles



Zoster Eye Disease Study


Condition:   Herpes Zoster Ophthalmicus
Interventions:   Drug: Masked Placebo;   Drug: Masked Oral Valacyclovir
Sponsors:   New York University School of Medicine;   National Eye Institute (NEI);   National Institutes of Health (NIH)
Not yet recruiting - verified April 2017


Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients


Condition:   Herpes Zoster
Intervention:   Biological: Zostavax vaccine
Sponsor:   HaEmek Medical Center, Israel
Recruiting - verified February 2017


Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age


Condition:   Herpes Zoster
Intervention:   Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
Sponsor:   GlaxoSmithKline
Active, not recruiting - verified April 2017


Herpes Zoster Prevalence in Frailty Consultations


Condition:   Herpes Zoster
Intervention:   Other: Medical Questionary
Sponsor:   University Hospital, Toulouse
Completed - verified July 2016



Optimal Timing of Zoster Vaccine After Zoster Illness


Condition:   Shingles
Intervention:   Biological: Zostavax
Sponsor:   Seoul National University Hospital
Recruiting - verified October 2016


Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.


Condition:   Herpes Zoster
Intervention:   Biological: Herpes Zoster Vaccine GSK1437173A
Sponsor:   GlaxoSmithKline
Recruiting - verified May 2017


Immune Response to Shingles Vaccination


Condition:   Shingles
Intervention:   Drug: Zoster Vaccine Live
Sponsors:   University of Washington;   Merck Sharp & Dohme Corp.
Recruiting - verified October 2016


Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier


Condition:   Herpes Zoster
Intervention:   Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
Sponsor:   GlaxoSmithKline
Active, not recruiting - verified January 2017


Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds


Conditions:   Shingles;   Herpes Zoster
Interventions:   Biological: Zostavax;   Biological: HZ/su vaccine;   Biological: Placebo
Sponsors:   University of Colorado, Denver;   GlaxoSmithKline
Active, not recruiting - verified February 2017


Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age


Condition:   Herpes Zoster
Intervention:   Biological: Herpes Zoster vaccine (GSK 1437173A)
Sponsor:   GlaxoSmithKline
Completed - verified January 2017


Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older


Condition:   Herpes Zoster
Interventions:   Biological: Herpes Zoster vaccine GSK 1437173A;   Biological: Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™
Sponsor:   GlaxoSmithKline
Completed - verified January 2017


Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster


Condition:   Herpes Zoster
Intervention:   Biological: Herpes Zoster vaccine (GSK1437173A)
Sponsor:   GlaxoSmithKline
Completed - verified March 2017


Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy


Condition:   Herpes Zoster
Interventions:   Biological: GSK 1437173A;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Completed - verified July 2016


Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers


Condition:   Herpes Zoster
Interventions:   Biological: Herpes zoster vaccine (GSK 1437173A);   Drug: Placebo
Sponsor:   GlaxoSmithKline
Completed - verified March 2017


Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older


Condition:   Herpes Zoster
Intervention:   Biological: Herpes zoster vaccine GSK1437173A
Sponsor:   GlaxoSmithKline
Completed - verified February 2017


Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A


Condition:   Herpes Zoster
Interventions:   Biological: Herpes Zoster vaccine GSK1437173A;   Biological: Placebo
Sponsor:   GlaxoSmithKline
Completed - verified April 2017


ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)


Conditions:   Herpes Zoster;   Shingles
Intervention:   Biological: ZOSTAVAX™
Sponsors:   Merck Sharp & Dohme Corp.;   Kaiser Permanente
Active, not recruiting - verified April 2017


Herpes Zoster Vaccine for Bone Marrow Transplant Donors


Condition:   Herpes Zoster
Intervention:   Biological: Zostavax
Sponsor:   University of Sydney
Recruiting - verified May 2017


Study of Long Term Immune Responses and Safety of the GSK Herpes Zoster Vaccine in Healthy Subjects


Condition:   Herpes Zoster
Intervention:   Procedure: Blood sample
Sponsor:   GlaxoSmithKline
Completed - verified March 2017


Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents


Conditions:   Immunosenescence;   Shingles
Intervention:   Biological: Varicella Zoster Virus Vaccine (Zostavax)
Sponsors:   University of Colorado, Denver;   National Institute on Aging (NIA);   Merck Sharp & Dohme Corp.
Active, not recruiting - verified January 2017


Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older


Condition:   Herpes Zoster
Interventions:   Biological: Herpes Zoster Vaccine GSK1437173A;   Biological: Placebo
Sponsor:   GlaxoSmithKline
Completed - verified March 2017


Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults


Condition:   Herpes Zoster
Intervention:   Biological: Herpes Zoster Vaccine GSK 1437173A
Sponsor:   GlaxoSmithKline
Completed - verified May 2017


Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years


Condition:   Herpes Zoster
Interventions:   Biological: Herpes zoster vaccine GSK1437173A;   Biological: Placebo
Sponsor:   GlaxoSmithKline
Completed - verified March 2017


Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)


Condition:   Shingles
Interventions:   Biological: zoster vaccine live (Oka/Merck);   Biological: Comparator: placebo (unspecified)
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified March 2017

Refine Your Search Advanced Search